
    
      This is an open-label, multi-center, cross-over study in male and female pediatric cancer
      patients, aged 6 to 12 years of age who are receiving at least 2 cycles of emetogenic
      chemotherapy requiring 5-HT3 antagonist treatment of up to 5 days duration. The study is
      designed to evaluate the safety and PK of transdermal granisetron (SancusoÂ® patch) in a
      pediatric population (aged 6 to 12 years), using a population PK approach.
    
  